Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI).
暂无分享,去创建一个
G. Burmester | T. Dörner | H. Schulze-Koops | H. Kellner | K. Krüger | H. Tony | A. Rubbert-Roth | M. Peters | M. Schmalzing | C. Iking-Konert | A. Engel | R. Kurthen | P. Kästner | H. Schwenke